Santhera Pharmaceuticals Holding AG
🇨🇭XSWX.SANNSwitzerlandNot reported
PriceCHF 15.22+0.20 (+1.33%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 4
- Medium: 0
- Low: 0
Financial leverage: a sudden drop below its trailing quarter average
Gross profit margin: a sudden drop below its trailing quarter average
Return on equity: a sudden spike above its trailing quarter average
Working capital turnover: a sudden spike above its trailing quarter average
Free with a Finzer account.
Profile
- Switzerland
Identity
- Exchange
- SIX Swiss Exchange . XSWX
- Type
- Stock
- ISIN
- CH0027148649
- CUSIP
- Not reported
Company
- Employees
- 78
- Headquarters
- Pratteln, United Kingdom
- Website
- https://www.santhera.com
Market
- Shares outstanding
- 13M
- Market cap
- CHF 197.43M
Highlights
- Market cap
- CHF 197.43M
- EPS LTM
- CHF 8.32
- P/E LTM
- 1.83calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CHF 170.33M+2,099.75%up year on year
- Net income
- CHF 94.28M+197.17%up year on year
- Gross margin
- 94.06%+339.15%up year on year
- Free cash flow
- CHF 70.78M+231.44%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Santhera Pharmaceuticals Holding AG is listed on SIX Swiss Exchange (Switzerland) under the ticker SANN. Its market capitalisation is CHF 197.43M, from 13M shares outstanding, as of . Across the 249 trading sessions to the shares traded between CHF 9.38 and CHF 18.84, and the last close of CHF 15.22 sits 62% of the way up that range. The company is headquartered in Pratteln, United Kingdom, and employs about 78 people. The same company also trades as S3F0 on Frankfurt Stock Exchange, and as 0QN1 on London Stock Exchange.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.